UroPharma has patented and developed the world’s first licensed ‘direct to bladder’ drug delivery system, that will be in the market by early 2023.
This overcomes clinical limitations and significant harms caused by the oral delivery of drugs intended for bladder therapy.
The design incorporates safety features intended to reduce costs associated with treating catheter acquired urinary tract infections caused by antibiotic resistance.
Urinary tract infections represent a substantial cost burden to the healthcare system and catheters are the biggest contributors to this global problem.
Urinary Tract Infections, Overactive Bladder, incontinence, Multiple Sclerosis and Spinal Cord Injury are a substantial reducer of quality of life with millions of people.
We’ll be very interested in your feedback and questions